Arix Bioscience Overview

  • Investor Type
  • Venture Capital

  • Status
  • Active

  • Professionals
  • 5

Professionals
  • Investments
  • 36

  • Portfolio
  • 15

  • Exits
  • 15

Exits

Arix Bioscience General Information

Description

Founded in 2016, Arix Bioscience is a venture capital firm based in London, United Kingdom. The firm seeks to invest in seed-stage companies, preclinical and clinical-stage assets, private or public companies operating across biotech, healthcare, and life science sectors.

Contact Information

Year Founded
2016
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Primary Office
  • Duke Street House
  • 50 Duke Street
  • London W1K 6JL
  • England, United Kingdom
+44 020 0000 0000

Arix Bioscience Investments & Acquisitions (36)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Sorriso Pharmaceuticals 22-Dec-2021 Early Stage VC 0000 Drug Discovery Startup 0000 0000
0000000 15-Dec-2021 00000 00000 000.00 Drug Discovery Generating Revenue 0000 0000
0000 00000000 01-Sep-2021 00000 00000 0000 Drug Discovery Generating Revenue 0000 0000
000000 23-Jul-2021 00000 00000 00000 Drug Discovery Generating Revenue 0000 0000
0000 00000000000 22-Mar-2021 00000 00000 0000 Drug Discovery Generating Revenue 000000000 00000000 00.0
000000 000 09-Mar-2021 0000 00000 Drug Discovery Startup 000000000 00000000 00.0
00000 00000000 05-Mar-2021 00000 00000 00000 Drug Discovery Pre-Clinical Trials 000000000 00000000 00.0
00000000 02-Jul-2020 00000 00000 00000 Drug Discovery Generating Revenue 00000000 00000 00.0
VelosBio 08-May-2020 Early Stage VC 0000 Drug Discovery Generating Revenue 000000 00000000 00.0
Imara 01-Feb-2020 Early Stage VC 000.00 Biotechnology Clinical Trials - Phase 2 0000 0000
You’re viewing 10 of 36 investments and acquisitions. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arix Bioscience Exits (15)

Company Name Exit Date Exit Type Exit Size
Aura Biosciences 02-Nov-2021 IPO 000.00
00000 00000000 08-Oct-2021 000 00000
000000 00000000000 28-Apr-2021 000000000000000000
000000 000 09-Mar-2021 000 00 00000000
0000000 0000000000 07-Jan-2021 000000 0000000000 00000
00000000 18-Dec-2020 000000000000000000 00.00
000000 00000000000 26-Oct-2020 000000 0000000000 000.00
00000 12-Mar-2020 000 000.00
Autolus 22-Jan-2020 Secondary Transaction - Open Market
Mitoconix 01-Jul-2019 Out of Business
You’re viewing 10 of 15 exits. Get the full list »

Arix Bioscience Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Arix Bioscience Team (23)

Name Title Deals Funds Boards Office
Robert Lyne Chief Executive Officer, Board Member & General Counsel, Legal London, United Kingdom
Mark Chin Managing Director 0 00 New York, NY
Laura Craig Team and Marketing Coordinator London, United Kingdom
Felix Breyer Ph.D Associate London, United Kingdom
Naseem Amin Chairman & Board Member 0 London, United Kingdom
You’re viewing 5 of 23 team members. Get the full list »

Arix Bioscience Co-Investors (106)

Name With Exits Lead Partner Series Industry
OrbiMed 5 0 0 Series chart Industry bar
Lundbeckfond Ventures 0 0 0 Series chart Industry bar
New Enterprise Associates 0 0 0 Series chart Industry bar
Pappas Capital 0 0 0 Series chart Industry bar
Sofinnova Investments 0 0 0 Series chart Industry bar
You’re viewing 5 of 106 co-investors. Get the full list »